시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 비교리스트
세계의 동종 T 세포 치료 시장 보고서(2024년)
Allogeneic T Cell Therapies Global Market Report 2024
상품코드 : 1596977
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 175 Pages
 라이선스 & 가격 (부가세 별도)
US $ 5,000 ￦ 7,234,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 7,500 ￦ 10,851,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 10,000 ￦ 14,469,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

동종 T세포 치료 시장 규모는 향후 몇 년동안 강력한 성장세를 보일 것으로 예상되며, 2028년까지 연평균 9.9%의 성장률로 16억 9,000만 달러에 달할 것으로 예상됩니다. 예측 기간 동안의 성장은 치료 적응증 확대, 세포 기반 면역 요법에 대한 수요 증가, 첨단 치료에 대한 인식 증가, 의료비 지출 증가, 유리한 상환 정책으로 인해 주도될 것으로 보입니다. 이 기간 동안 예상되는 주요 동향으로는 연구개발의 발전, 개인 맞춤형 의료의 부상, 기성 치료제 개발, 세계 시장 확대, 전략적 제휴, 규제 환경의 변화 등이 있습니다.

암 발병률 증가는 동종 T세포 치료 시장의 성장을 견인할 것으로 예상됩니다. 암은 체내 비정상적인 세포의 무질서한 증식과 확산으로 특징지어지는 질병군입니다. 암 환자 증가는 평균 수명 증가, 생활습관 변화, 환경 노출, 감염, 유전적 소인, 생식 패턴의 변화 등의 요인과 관련이 있으며, 이 모든 것이 암 발생률과 발견률 증가에 기여하고 있습니다. 동종 T세포 치료는 유전자 조작된 공여자의 T세포를 주입하여 암세포를 표적으로 삼아 파괴하는 방식으로, 2024년 5월 미국 국립암연구소에 따르면 미국 내 암 생존자 수는 약 1,810만 명이며, 2032년에는 2,250만 명으로 증가할 것으로 예상하고 있습니다. 2040년에는 연간 신규 암 환자 수가 2,990만 명에 달하고, 암 관련 사망자는 1,530만 명으로 증가할 것으로 예상됩니다. 이러한 추세는 동종 T세포 치료 시장의 성장을 가속할 것으로 예상됩니다.

동종 T세포 치료 시장의 주요 기업들은 치료 효과를 높이고 치료 옵션을 확대하기 위해 혁신적인 키메라 항원 수용체(CAR) T세포 치료제 프로그램 개발에 주력하고 있습니다. 이러한 선도적인 노력은 암에 대한 CAR T세포 치료의 효율성, 접근성 및 전달을 개선하는 것을 목표로 하고 있습니다. 예를 들어, 미국에 본사를 둔 생명공학 기업 Allogene Therapeutics Inc.는 2022년 10월 CAR T 치료의 전달 및 접근성 문제를 해결하기 위해 CAR T Together라는 이니셔티브를 출범했습니다. 이 프로그램은 동종 CAR T 치료제 개발을 촉진하기 위해 임상시험 등록을 간소화하고 종양 전문의 간의 협력을 촉진하는 것을 목표로 합니다. 환자 자신의 세포를 사용하는 자가 치료와 달리 동종 치료는 건강한 기증자의 T세포에 의존하기 때문에 보다 효율적인 생산 공정을 가능하게 합니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 거시경제 시나리오

제5장 세계 시장 규모와 성장

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 개요

제31장 기타 주요 기업 및 혁신 기업

제32장 경쟁 벤치마킹

제33장 경쟁 대시보드

제34장 주요 인수합병(M&A)

제35장 향후 전망과 잠재적인 분석

제36장 부록

LSH
영문 목차

영문목차

Allogeneic T cell therapies represent an advanced medical approach where T cells, critical to the immune system, are sourced from a donor and utilized to attack cancer cells in a recipient. These therapies are primarily applied in the treatment of challenging cancers that are resistant to conventional therapies.

The key forms of allogeneic T cell therapies include chimeric antigen receptor (CAR) T cell therapies and T cell receptor (TCR) therapies. CAR T-cell therapies are a type of immunotherapy where T-cells are genetically engineered to target and eliminate cancer cells by recognizing specific proteins on them. Targeted antigens in these therapies include CD19, CD20, EgfrvIII, GD2, CD22, CD30, CD33, Meso, HER1, among others. These therapies address various conditions such as cancer, autoimmune disorders, and infectious diseases, with applications spanning hospitals, specialty clinics, research institutions, and other healthcare facilities.

The allogeneic T cell therapies market research report is one of a series of new reports from The Business Research Company that provides allogeneic T cell therapies market statistics, including the allogeneic T cell therapies industry's global market size, regional shares, competitors with an allogeneic T cell therapies market share, detailed allogeneic T cell therapies market segments, market trends, and opportunities, and any further data you may need to thrive in the allogeneic T cell therapies industry. This allogeneic T cell therapies market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The allogeneic T cell therapies market size has grown strongly in recent years. It will grow from $1.06 billion in 2023 to $1.16 billion in 2024 at a compound annual growth rate (CAGR) of 9.8%. The growth during the historical period can be attributed to key factors such as regulatory approvals, a rising incidence of cancer, an increase in clinical trials, government funding, and an expanding geriatric population.

The allogeneic T cell therapies market size is expected to see strong growth in the next few years. It will grow to $1.69 billion in 2028 at a compound annual growth rate (CAGR) of 9.9%. The growth during the forecast period is expected to be driven by expanding treatment indications, increased demand for cell-based immunotherapies, heightened awareness of advanced therapies, rising healthcare expenditures, and favorable reimbursement policies. Key trends anticipated in this period include advancements in research and development, the rise of personalized medicine, the development of off-the-shelf therapies, global market expansion, strategic partnerships, and changes in the regulatory landscape.

The growing incidence of cancer is expected to drive the expansion of the allogeneic T cell therapies market. Cancer is a group of diseases marked by the uncontrolled proliferation and spread of abnormal cells in the body. The rise in cancer cases is linked to factors such as increased life expectancy, lifestyle changes, environmental exposures, infections, genetic predispositions, and shifts in reproductive patterns, all of which contribute to a higher incidence and detection of cancer. Allogeneic T cell therapies, which involve infusing genetically engineered donor T cells to target and destroy cancer cells, are increasingly being used in cancer treatment. According to the National Cancer Institute in May 2024, there were approximately 18.1 million cancer survivors in the U.S., a number projected to increase to 22.5 million by 2032. By 2040, the number of new cancer cases annually is expected to reach 29.9 million, with cancer-related deaths rising to 15.3 million. These trends are expected to propel the growth of the allogeneic T cell therapies market.

Leading companies in the allogeneic T cell therapies market are focusing on developing innovative chimeric antigen receptor (CAR) T-cell therapy programs to enhance treatment effectiveness and broaden therapeutic options. These advanced initiatives aim to improve the efficiency, accessibility, and delivery of CAR T-cell therapies for cancer. For example, in October 2022, Allogene Therapeutics Inc., a U.S.-based biotechnology company, launched CAR T Together, an initiative aimed at addressing challenges related to the delivery and accessibility of CAR T therapies. The program seeks to streamline clinical trial enrollment and foster collaboration among oncologists to expedite the development of allogeneic CAR T therapies. Unlike autologous therapies, which use a patient's own cells, allogeneic therapies rely on T cells from healthy donors, allowing for more efficient manufacturing processes.

In January 2023, AstraZeneca Plc, a UK-based pharmaceutical company, acquired Neogene Therapeutics Inc. for an undisclosed sum. This acquisition is part of AstraZeneca's strategy to advance innovative treatments and bolster its oncology capabilities, particularly in developing therapies for solid tumors that target cancer-specific mutations. Neogene Therapeutics Inc. is a U.S.-based biotechnology firm specializing in allogeneic T cell therapies.

Major companies operating in the allogeneic t cell therapies market are Bristol-Myers Squibb Company, Novartis AG, Gilead Sciences Inc., Immatics NV, Sangamo Therapeutics Inc., Poseida Therapeutics Inc., Fate Therapeutics Inc., Atara Biotherapeutics Inc., Sorrento Therapeutics Inc, Autolus Therapeutics Plc, MaxCyte Inc., Tessa Therapeutics Pte Ltd., Cell Medica Inc., Enlivex Therapeutics Ltd., Cellectis SA, Adaptimmune Therapeutics Plc, Medigene AG, Celyad Oncology SA, Allogene Therapeutics Inc, Bellicum Pharmaceuticals Inc.

North America was the largest region in the allogeneic T cell therapies market in 2023. The regions covered in the allogeneic t cell therapies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the allogeneic t cell therapies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The allogeneic T cell therapies market includes revenues earned by entities providing services such as allogeneic CAR-t cell therapy, allogeneic TCR-t cell therapy, allogeneic NK or T cell therapy, off-the-shelf allogeneic t cell therapy, allogeneic virus-specific t cell therapy, and universal donor t cell therapies. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Allogeneic T Cell Therapies Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on allogeneic T cell therapies market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for allogeneic T cell therapies ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The allogeneic T cell therapies market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of COVID-19 on supply chains and consumption patterns.

Scope

Table of Contents

1. Executive Summary

2. Allogeneic T Cell Therapies Market Characteristics

3. Allogeneic T Cell Therapies Market Trends And Strategies

4. Allogeneic T Cell Therapies Market - Macro Economic Scenario

5. Global Allogeneic T Cell Therapies Market Size and Growth

6. Allogeneic T Cell Therapies Market Segmentation

7. Allogeneic T Cell Therapies Market Regional And Country Analysis

8. Asia-Pacific Allogeneic T Cell Therapies Market

9. China Allogeneic T Cell Therapies Market

10. India Allogeneic T Cell Therapies Market

11. Japan Allogeneic T Cell Therapies Market

12. Australia Allogeneic T Cell Therapies Market

13. Indonesia Allogeneic T Cell Therapies Market

14. South Korea Allogeneic T Cell Therapies Market

15. Western Europe Allogeneic T Cell Therapies Market

16. UK Allogeneic T Cell Therapies Market

17. Germany Allogeneic T Cell Therapies Market

18. France Allogeneic T Cell Therapies Market

19. Italy Allogeneic T Cell Therapies Market

20. Spain Allogeneic T Cell Therapies Market

21. Eastern Europe Allogeneic T Cell Therapies Market

22. Russia Allogeneic T Cell Therapies Market

23. North America Allogeneic T Cell Therapies Market

24. USA Allogeneic T Cell Therapies Market

25. Canada Allogeneic T Cell Therapies Market

26. South America Allogeneic T Cell Therapies Market

27. Brazil Allogeneic T Cell Therapies Market

28. Middle East Allogeneic T Cell Therapies Market

29. Africa Allogeneic T Cell Therapies Market

30. Allogeneic T Cell Therapies Market Competitive Landscape And Company Profiles

31. Allogeneic T Cell Therapies Market Other Major And Innovative Companies

32. Global Allogeneic T Cell Therapies Market Competitive Benchmarking

33. Global Allogeneic T Cell Therapies Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Allogeneic T Cell Therapies Market

35. Allogeneic T Cell Therapies Market Future Outlook and Potential Analysis

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기